Furthermore, a study suggested that lncRNA CRAL functions as a competitive endogenous RNA that reverses cisplatin resistance in GC by modulating the miR-505/CYLD/Akt signaling pathway (130). This evidence concerns the gene AKT1 and gastric cancer.